Mycophenolate Mofetil in Pregnancy After Renal Transplantation: A Case of Major Fetal Malformations
- 1 May 2004
- journal article
- case report
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 103 (5) , 1091-1094
- https://doi.org/10.1097/01.aog.0000124986.32858.ba
Abstract
Mycophenolate mofetil has teratogenic properties in rats and rabbits. Previous human studies have reported an increased rate of fetal losses with its use. We report a case of major fetal malformations due to mycophenolate mofetil. The patient was treated with mycophenolate mofetil before conception and during the first trimester of pregnancy. The fetus had multiple malformations, specifically, facial dysmorphology and midline anomalies, including agenesis of the corpus callosum. This case of fetal malformation attributable to mycophenolate mofetil must be taken into consideration when considering pregnancy in an organ-transplant recipient.Keywords
This publication has 5 references indexed in Scilit:
- In utero exposure to immunosuppressive drugs: experimental and clinical studiesPediatric Nephrology, 2002
- KIDNEY TRANSPLANTATION DURING THE FIRST TRIMESTER OF PREGNANCY: IMMUNOSUPPRESSION WITH MYCOPHENOLATE MOFETIL, TACROLIMUS, AND PREDNISONETransplantation, 2001
- REVIEW OF THE COURSE AND OUTCOME OF 100 PREGNANCIES IN 84 WOMEN TREATED WITH TACROLIMUS1Transplantation, 2000
- Pregnancy in chronic renal insufficiency and end-stage renal diseaseAmerican Journal of Kidney Diseases, 1999
- Repeated successful pregnancies after kidney transplantation in 102 women (Report by the EDTA RegistryNephrology Dialysis Transplantation, 1996